Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Maria Trinh

Physician Assistant, Medical Pasadena, CA Physician Assistant

NPI 1023369667 CMS profile 10558071

473 N Fair Oaks Ave, Pasadena, CA 91103

Open in the dashboard

General payments

$14,289

640 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maria Trinh of Pasadena, CA is reported in the CMS Open Payments database as having received $14,289 across 640 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,657 153
2024 General $4,149 177
2023 General $3,443 165
2022 General $2,088 97
2021 General $952 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Trinh
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Maria Trinh were reported at $3,657. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Maria Trinh Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $952 $156 $41–$563 $132
2022 $2,088 $185 $55–$649 $149
2023 $3,443 $199 $58–$717 $160
2024 $4,149 $206 $62–$740 $164
2025 $3,657 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $2,083 58 payments
  2. Regeneron Healthcare Solutions, Inc. $1,422 43 payments
  3. Incyte Corporation $1,273 80 payments
  4. AbbVie, Inc. $1,047 43 payments
  5. Janssen Biotech, Inc. $844 31 payments
  6. E.R. Squibb & Sons, L.L.C. $833 51 payments
  7. UCB, Inc. $817 30 payments
  8. LEO Pharma Inc. $781 47 payments
  9. Pfizer Inc. $726 41 payments
  10. Sun Pharmaceutical Industries Inc. $706 37 payments
  11. Other $3,757 179 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,607 629 payments
  2. Education $682 11 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $2,083 58 payments
  2. OPZELURA $1,206 79 payments
  3. DUPIXENT Inflammation And Immunology $1,199 37 payments
  4. TREMFYA $828 30 payments
  5. SOTYKTU $800 50 payments
  6. ADBRY $717 44 payments
  7. Otezla $685 33 payments
  8. CIBINQO $605 35 payments
  9. Bimzelx $600 20 payments
  10. Zoryve $558 33 payments
  11. Other $6,532 308 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,338

Median for Physician Assistant: 241

Drug cost

$921,223

Median for Physician Assistant: $4,110

Branded share of claims

17.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tremfya Guselkumab Brand 21 $280,427
Otezla Apremilast Brand 46 $220,730
Cosentyx Sensoready (2 Pens) Secukinumab Brand 18 $132,697
Dupixent Pen Dupilumab Brand 34 $125,923
Opzelura Ruxolitinib Phosphate Brand 47 $89,735
Zoryve Roflumilast Brand 42 $39,658
Pimecrolimus Generic 25 $5,739
Tacrolimus Generic 35 $4,104
Ketoconazole Generic 227 $3,138
Fluorouracil Generic 37 $2,364

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $578
  • Regeneron Healthcare Solutions, Inc. $437
$1,015 34 —
Bimzelx
  • UCB, Inc. $303
$303 — —
ADBRY
  • LEO Pharma Inc. $224
$224 — —
OPZELURA
  • Incyte Corporation $221
$221 47 —
VTAMA
  • Dermavant Sciences, Inc. $219
$219 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

640 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record